Navigation Links
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
Date:4/22/2008

Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy

and New Insights into Mechanism of Action of Nitazoxanide

MILAN, Italy, April 23 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV) infection are being communicated in four presentations made at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), held in Milan, Italy this week.

"These new studies confirm earlier data suggesting synergistic activity between nitazoxanide and peginterferon in genotype 4 patients and provide a first look at sustained virologic response in a limited number of genotype 1 patients," said Jean-Francois Rossignol, M.D., Director of the Romark Institute for Medical Research and discoverer of nitazoxanide. "These data also provide interesting insights into the mechanism of action of nitazoxanide and confirm previous findings related to its safety."

The four presentations include:

-- An oral presentation, titled, "Randomized Controlled Trial of

Nitazoxanide-Peginterferon-Ribavirin, Nitazoxanide-Peginterferon and

Peginterferon-Ribavirin in the Treatment of Patients with Chronic

Hepatitis C Genotype 4," reported final 24-week post-treatment

sustained virologic response (SVR) rates for the company's STEALTH C-1

trial.

In the trial, 96 treatment-naive patients with chronic hepatitis C

genotype 4 were randomized into three groups to receive either 48 weeks

of standard of care (SOC) treatment (n=40), 12 weeks of nitazoxanide

followed by 36 weeks of nitazoxanide plus peginterferon (a dual regimen,

n=28), or 12 weeks of nitazoxanide followed by 36 weeks of nitazoxanide

plus SOC with peginterferon plus ribavirin (a triple regimen, n=28). An

additional 24 interferon-experi
'/>"/>

SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... pipeline and new product development efforts. In the second ... Phase 2a study of AZ-002 (Staccato ® ... of patients with acute repetitive seizures.  Additionally, Alexza ... candidates for development - AZ-008 and AZ-009 - ...
(Date:7/31/2014)... Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... development of its lead molecule, Anatabine Citrate, in ... Quotient Clinical, The Translational Pharmaceutics Company, based in the ... its early development programs. The Company expects ... end of the third quarter with the Medicines Healthcare ...
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3
... 11, 2011 General Dynamics Information Technology, a ... GD ), has been awarded a contract to ... into the Vincennes University hospital simulation laboratory in ... environment for the continuing education of healthcare professionals ...
... 2011 Medical Insight, Inc. , a progressive media ... debut THE Asian Aesthetic Guide ™ ... in Seoul, Korea. This new publication, directed toward aesthetic physicians, ... THE Asian Aesthetic Guide , available in ...
Cached Medicine Technology:General Dynamics' InForceā„¢ Training Toolkit to Support Vincennes University Hospital Simulation Lab 2Medical Insight to Launch THE Asian Aesthetic Guide at World Congress of Dermatology 2Medical Insight to Launch THE Asian Aesthetic Guide at World Congress of Dermatology 3
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 Millions ... that affects the legs and in some cases the ... estimates state that about 17 million women in the ... of women dealing with the pain, embarrassment and discomfort ... and even some physicians are unaware that this is a ...
(Date:8/1/2014)... 01, 2014 Register to join the webinar ... most active years on record for life sciences investing. IPOs ... represented 22 percent of all venture dollars spent in 2013. ... high valuations. , However, 2014 is proving more of ... by Silicon Valley Bank, while life sciences IPOs are losing ...
(Date:7/31/2014)... 1, 2014) Women over the age of 65 ... for obesity, greater struggles against poverty and higher rates ... in the August issue of Annals of Allergy, ... American College of Allergy, Asthma and Immunology (ACAAI), outlines ... and offers practical solutions to improve their care. ...
(Date:7/31/2014)... The 2013 PolyU TSI hit ... from 75.07 in 2012. The index measures inbound ... integrates them into an overall index. The 2013 ... satisfied with Hong Kong over time. , The ... service performance in Hong Kong are attractions (79.27) ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now ... a Systematic Review of Sexual Satisfaction . ... International Journal of Clinical and Health Psychology. , This ... need to have accurate information about sexual satisfaction so ... The material provides a systematic review of 197 ...
Breaking Medicine News(10 mins):Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
... N.J., Jan. 16 BD (Becton,Dickinson and Company) (NYSE: ... that it will host a live webcast of its ... 1 p.m. (ET)., The webcast can be accessed ... will be available for replay through Tuesday,February 5, 2008., ...
... Global Disease,Burden, WASHINGTON, Jan. 16 A ... undernutrition published in the,leading international medical journal The ... into their adult life if proper nutrition,interventions are ... The Lancet,s,Series on Maternal and Child Undernutrition reviews ...
... OMI Medical Imaging, Inc. (OMI),announced today that it and ... U.S. Bankruptcy Court for the Southern District of,Florida on ... reimbursement cuts took effect on,January 1, 2007, the company ... secured lenders., OMI operates 21 free standing imaging ...
... hormone therapy, study finds , , WEDNESDAY, Jan. 16 (HealthDay ... the risk of breast cancer in postmenopausal women, it ... malignancy: lobular breast cancer. , The authors of a ... of Cancer Epidemiology, Biomarkers & Prevention , also ...
... CINCINNATI Human evolution has created enhancements in key ... so-called guardian of the genome by creating additional ... to guard against DNA damage that could cause cancer ... of scientists led by Cincinnati Childrens Hospital Medical Center ...
... January 10, Dr. Marlies Van Hoef,CEO of Transplant ... an all-new interview with http://www.wallst.net .,Topics covered ... company, recent,press, the market opportunity and upcoming milestones ... interview in its entirety, visit the Company website ...
Cached Medicine News:Health News:New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health 2Health News:New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health 3Health News:New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health 4Health News:New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health 5Health News:New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health 6Health News:OMI Medical Imaging, Inc. and Affiliated Companies File Chapter 11 Reorganization 2Health News:HRT Raises Risk of Lobular Breast Cancer 2Health News:HRT Raises Risk of Lobular Breast Cancer 3Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 2Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 3Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 4Health News:WallSt.net Updates Investment Community Through All-New Interview With Transplant Creations 2
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
The new Medpor Superior Lateral Orbital Rim is designed for subtle augmentation of the lateral and superior or orbital rims in patients who are hypoplasic in the superior-lateral aspect of the orbita...
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
1.5 mm inner cutting edge....
Medicine Products: